Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (HPXeMR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02272049 |
Recruitment Status :
Recruiting
First Posted : October 22, 2014
Last Update Posted : December 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Respiratory Disorders | Drug: Hyperpolarized 129 Xenon | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Use of Hyperpolarized 129 Xe MR Lung Imaging in Children and Adults |
Actual Study Start Date : | December 2014 |
Estimated Primary Completion Date : | August 24, 2023 |
Estimated Study Completion Date : | August 24, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Hyperpolarized 129 Xenon
Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
|
Drug: Hyperpolarized 129 Xenon
During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
Other Name: HP 129 Xe |
- Correlation of ventilated volume predictions obtained with 129Xe MRI vs. 1H MRI [ Time Frame: Day 1 ]quantify the measurement agreement between the ventilated volume of healthy lungs predicted via 129 Xe MRI and the ventilated volume of the pleural cavity predicted via proton MRI

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Ages 6 and up
- Participant must be able to hold breath for up to 16 seconds
Exclusion Criteria:
- History of heart defect
- Pregnancy or positive pregnancy test
- History of uncontrolled asthma defined for this study as requiring use of rescue inhaler ≥ 2 times in past month
- Symptoms of respiratory infection (loose or productive cough or wheeze), chest tightness, or sinus infection within past week
- Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula
- Participant is claustrophobic and unable to tolerate the imaging.
- Standard MRI exclusions (metal, implants)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02272049
Contact: Carrie Stevens, BS | 513-636-9973 | Carrie.Stevens@cchmc.org | |
Contact: Kelly Thornton, BS | 513-636-0604 | Kelly.Thornton@cchmc.org |
United States, Ohio | |
Cincinnati Children's Hospital Medical Center | Recruiting |
Cincinnati, Ohio, United States, 45229 | |
Principal Investigator: Jason C. Woods, PhD |
Principal Investigator: | Jason C. Woods, PhD | Children's Hospital Medical Center, Cincinnati |
Responsible Party: | Children's Hospital Medical Center, Cincinnati |
ClinicalTrials.gov Identifier: | NCT02272049 |
Other Study ID Numbers: |
2014-5279 IND 123577 ( Other Identifier: FDA ) |
First Posted: | October 22, 2014 Key Record Dates |
Last Update Posted: | December 19, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Respiratory |
Respiration Disorders Respiratory Tract Diseases Xenon Anesthetics, Inhalation |
Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |